NASDAQ: VIVSVivosim Labs Inc Stock
$1.73-0.13 (-6.99%)
Updated Apr 28, 2025
VIVS Price
$1.73
Fair Value Price
$0.16
Market Cap
$2.52M
52 Week Low
$1.56
52 Week High
$21.96
P/E
-0.17x
P/B
6.91x
P/S
68.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$122.00k
Earnings
-$12.39M
Gross Margin
95.9%
Operating Margin
-10,145.9%
Profit Margin
-10,151.6%
Debt to Equity
9.56
Operating Cash Flow
-$10M
Beta
0.74
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VIVS Overview
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. The company was incorporated in 2007 and is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VIVS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VIVS
Ranked#178 of 464
Ranked#178 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.85 | A | |
| $8.00 | A | |
| $23.63 | A |
Be the first to know about important VIVS news, forecast changes, insider trades & much more!
VIVS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VIVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VIVS ($1.73) is overvalued by 996% relative to our estimate of its Fair Value price of $0.16 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VIVS ($1.73) is not significantly undervalued (996%) relative to our estimate of its Fair Value price of $0.16 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VIVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VIVS due diligence checks available for Premium users.
Valuation
VIVS fair value
Fair Value of VIVS stock based on Discounted Cash Flow (DCF)
Price
$1.73
Fair Value
$0.16
Overvalued by
996.00%
VIVS ($1.73) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VIVS ($1.73) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VIVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VIVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
-163.54x
Market
29.44x
VIVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.91x
Industry
4.32x
VIVS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VIVS's financial health
Profit margin
Revenue
$24.0k
Net Income
-$3.4M
Profit Margin
-14,362.5%
VIVS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VIVS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.8M
Liabilities
$3.5M
Debt to equity
9.56
VIVS's short-term liabilities ($2.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VIVS's short-term assets ($2.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VIVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VIVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.8M
Investing
$4.0k
Financing
-$216.0k
VIVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VIVS vs Biotech Stocks
Vivosim Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.